You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Nucala vial packshot

Nucala (mepolizumab)

Introducing Nucala: A targeted anti IL-5 therapy for adult patients with severe refractory eosinophilic asthma.

Nucala overview booklet

 Nucala overview  booklet

 For efficacy, safety and practical  information.

 Download your copy - PDF (4.1MB)

What is it like to live with severe asthma?

Hear first-hand from a severe asthma patient.

Read more

Nucala patient support booklet

 Patient support
 booklet

 For patients who are prescribed Nucala.

 Download booklet - PDF (1MB)

 Order hard copies

Access and availability

This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

Nucala is a registered trademark of the GlaxoSmithKline group of companies